Literature DB >> 3281740

Congestive heart failure.

G W Moe1, P W Armstrong.   

Abstract

Congestive heart failure (CHF) is a condition that is increasing in incidence and is associated with significant morbidity and mortality rates. The main abnormality that underlies CHF is depressed myocardial function. The resulting decrease in cardiac output activates several peripheral compensatory mechanisms, which may further impair ventricular function and worsen the prognosis. Although systolic dysfunction is the traditional descriptor of CHF, diastolic dysfunction is increasingly recognized as a distinct entity. In prescribing therapy the predominant type of ventricular dysfunction and the peripheral components of the heart failure should be identified. The ultimate aim is to alleviate symptoms, minimize complications and prolong survival. Recent data from two multicentre trials have suggested that vasodilators can achieve these goals. Trials are under way to assess the impact of early vasodilator therapy on CHF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281740      PMCID: PMC1267773     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  18 in total

Review 1.  Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094

2.  Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.

Authors:  C V Leier; P Huss; R D Magorien; D V Unverferth
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

3.  Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study.

Authors:  B L Kramer; B M Massie; N Topic
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

4.  Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.

Authors:  B M Massie; B Kramer; F Haughom
Journal:  Circulation       Date:  1981-12       Impact factor: 29.690

5.  Dose requirements of hydralazine in patients with severe chronic congestive heart failure.

Authors:  M Packer; J Meller; N Medina; R Gorlin; M V Herman
Journal:  Am J Cardiol       Date:  1980-03       Impact factor: 2.778

6.  Tolerance to organic nitrates: clinical and experimental perspectives.

Authors:  P W Armstrong; J A Moffat
Journal:  Am J Med       Date:  1983-06-27       Impact factor: 4.965

7.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia.

Authors:  V J Dzau; M Packer; L S Lilly; S L Swartz; N K Hollenberg; G H Williams
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

8.  Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.

Authors:  B Massie; K Chatterjee; J Werner; B Greenberg; R Hart; W W Parmley
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

9.  Heart failure in outpatients: a randomized trial of digoxin versus placebo.

Authors:  D C Lee; R A Johnson; J B Bingham; M Leahy; R E Dinsmore; A H Goroll; J B Newell; H W Strauss; E Haber
Journal:  N Engl J Med       Date:  1982-03-25       Impact factor: 91.245

10.  Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure.

Authors:  A E Raine; P Erne; E Bürgisser; F B Müller; P Bolli; F Burkart; F R Bühler
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.